Shares of Moderna Inc. MRNA, -3.58% gained 2.2% in premarket trading on Thursday after the company reported half a million dollars in sales of its COVID-19 vaccine in the fourth quarter of last year. The company had a loss of $272,000, or 69 cents per share, in the fourth quarter of 2020, compared with a loss of $123,000, or 37 cents per share, in the same quarter a year ago. The FactSet consensus was for a loss of 34 cents. It had revenue of $570.7 million in the fourth quarter of last year, up from $14.1 million in the same quarter ago, as its COVID-19 vaccine began to be distributed in several countries around the world, including the U.S. The FactSet consensus was $279 million in revenue for the quarter. The vaccine is the first authorized product in the company’s history. Moderna said it plans to produce at least 700 million doses of its vaccine in 2021, up from a previous low-end range estimate of 600 million, with a new goal of making 1.4 billion doses in 2022. The company said it has concluded enrollment in a clinical trial testing the COVID-19 vaccine in teens, and a Phase 2 trial for kids between the ages of 6 months and 11 year olds is also expected to begin in the “near-term.” Moderna’s stock has rallied 509.4% over the past 12 months, while the broader S&P 500 SPX, +1.14% is up 21.7%.
View Article Origin Here
